Trinity Biotech plc SEC filings document foreign-issuer reports furnished on Form 6-K for its diagnostics, diabetes management, and health technology operations. The filings record announcements tied to Premier Hb9210 diabetes testing, CGM+ biosensor development, EpiCapture prostate cancer diagnostics, North America commercial operations, trading updates, and the Comprehensive Transformation Plan.
The company’s filings also disclose ADS and ordinary-share capital matters, including a standby equity purchase agreement; credit-agreement waivers and covenant deferrals; Nasdaq listing-compliance notices for the ADSs; and incorporation by reference into Form S-8 registration statements. These records describe the formal reporting framework for Trinity Biotech as a foreign private issuer using Form 20-F reporting status.
Trinity Biotech plc reported that shareholders at its September 30, 2026 annual general meeting approved all proposed resolutions, each with at least 95% of votes cast.
Shareholders re-appointed Grant Thornton as statutory auditor until the conclusion of the next annual general meeting at which accounts are laid before the company, authorized the board to fix the statutory auditor’s remuneration, and re-appointed Dr Andrew Omidvar as a director.
Trinity Biotech plc (TRIB), through its Trinovium subsidiary, has signed a contract with Red Team Investments (RTI) to collaborate on advanced liquid cooling solutions for AI, high-performance computing and modular data center infrastructure. The agreement makes RTI a commercial pilot customer for Trinovium’s cooling fluids and analytical systems in a U.S. data center deployment, with paid product supply as part of the pilot.
The collaboration focuses on developing and deploying direct-to-chip liquid cooling, initially through integration planning, product testing, pilot deployment, and subsequent performance-data collection to guide product refinement, scale-up needs and broader commercial opportunities. Trinity Biotech positions Trinovium’s offering around healthcare-grade fluid manufacturing, ultra-high-purity aqueous chemistry, corrosion protection and an emerging fluid-health monitoring platform using analytical technologies such as connected electrochemical sensing and mass spectrometry.
The company notes that AI-driven data center power densities are increasing and cites third-party projections that the data center liquid cooling market could expand significantly over the coming years, framing this contract as a step toward real-world commercial validation of Trinovium’s technology.
TRINITY BIOTECH PLC (TRIB) reports that its 2026 Annual General Meeting will be held at its registered office in Bray, County Wicklow, Ireland, on September 30, 2026 at 10:00 am. Shareholders will vote on reappointing Grant Thornton as statutory auditor, authorising the Board to fix the auditors’ remuneration, and re-appointing Dr Andrew Omidvar as a director.
The company explains voting procedures for both registered shareholders and holders of American Depositary Receipts, including proxy submission, the use of a poll for each resolution, and that the record date is September 1, 2026. The 2025 Annual Report and AGM materials are furnished as exhibits and incorporated by reference into existing registration statements.
Trinity Biotech plc (TRIB) reported operational progress in its diagnostics business and addressed its Nasdaq listing status. The company appointed Jordi Romero as Head of Commercial Operations – Europe to strengthen commercial execution, and continued rolling out an upgraded high-capacity HbA1c column system for its Premier Hb9210™ analyser in three major international markets.
Trinity has completed manufacture of approximately 9 million TrinScreen HIV tests under a new outsourced manufacturing model and begun outsourced production of Uni-Gold™ HIV, aiming for improved gross margins, manufacturing efficiency and working capital use, though it notes potential quarter-to-quarter revenue variability during ramp-up. The company also expanded its PrePsia™ early preeclampsia prediction platform patent estate to nine granted patents across Europe and the United States and plans to launch PrePsia™ via its New York State-approved reference laboratory.
On the listing front, Trinity received a Nasdaq staff determination on August 28, 2026, after not regaining compliance with the $15 million minimum market value of publicly held shares requirement by August 18, 2026. The company will request a hearing before a Nasdaq Hearings Panel, which would stay any suspension or delisting action and could allow an extension of up to February 24, 2027, although there is no assurance of a favorable outcome.
TRINITY BIOTECH PLC (TRIB) filed Post-Effective Amendment No. 2 to its Form F-1 registration statement to terminate a previously registered standby equity facility and deregister unsold securities. The original F-1 registered 705,659,320 Class A ordinary shares, which were represented by American Depositary Shares (ADSs).
The ADS ratio was changed on July 24, 2026 from one ADS representing 20 ordinary shares to one ADS representing 600 ordinary shares, equivalent to a one-for-thirty reverse ADS split; after this change, the registered ordinary shares were represented by 1,176,099 ADSs. Under a Standby Equity Purchase Agreement with YA II PN, LTD., the company could sell ADSs for up to $25 million, but this agreement was terminated effective July 7, 2026. As a result, the company is removing from registration 675,048,580 ordinary shares, represented by 1,125,081 ADSs, that remained registered but unsold.
TRINITY BIOTECH PLC (TRIB) is filing Post-Effective Amendment No. 2 to its Form F-1 registration statement originally covering 705,659,320 Class A ordinary shares, which were previously represented by 35,282,966 ADSs at a ratio of one ADS to 20 ordinary shares.
Effective July 24, 2026, the ADS ratio changed to one ADS representing 600 ordinary shares, resulting in these registered shares being represented by 1,176,099 ADSs. Under a February 24, 2026 Standby Equity Purchase Agreement, the company could sell ADSs to YA II PN, LTD. for up to $25 million, but this agreement was terminated effective July 7, 2026. Following this termination, the company is removing from registration 675,048,580 ordinary shares, represented by 1,125,081 ADSs, that remained registered but unsold.
Trinity Biotech plc, through its Trinovium subsidiary, has entered into a strategic collaboration with Echelon Data Centres to develop advanced liquid cooling solutions for AI and high-density computing infrastructure. Trinovium will contribute ultra-high-purity fluid manufacturing and analytical technologies, while Echelon brings large-scale hyperscale data center design and operational expertise, including more than 700 MW of capacity under development and over 1.4 GW of secured capacity. Initial work will focus on direct-to-chip cooling fluids, thermal management systems and modular liquid cooling solutions tailored for AI workloads. Trinovium is also developing a fluid health and system intelligence platform intended to create a recurring, data-driven revenue stream around monitoring coolant purity, corrosion, contamination and microbial growth in liquid cooling systems.
Trinity Biotech plc entered into a further amendment of its term loan facility with Perceptive Credit Holdings III, LP, providing a $7.0 million investment made up of about $2.5 million in new debt funding and about $4.5 million of capitalized interest. Lenders also granted a limited waiver of the minimum liquidity covenant for June, July and August 2026 after the company fell below required unrestricted cash levels.
The company reported preliminary revenues of about $10.5 million for the quarter ended June 30, 2026, broadly in line with the prior quarter, while it continues an operational and strategic transformation focused on its CGM+ continuous glucose monitoring platform, diagnostics portfolio, and Trinovium liquid cooling solutions for AI data centers. On August 7, 2026, it received confirmation that it had regained compliance with Nasdaq’s minimum bid price rule after its ADSs closed at or above $1.00 for 10 consecutive business days from July 24 to August 6, 2026. As of August 13, 2026, it had 487,879,340 ordinary shares outstanding, with each Nasdaq-listed ADS representing 600 ordinary shares.
Trinity Biotech plc announced a strategic collaboration agreement with Latch Medical Limited, together with an agreed-in-principle strategic equity investment, to develop biosensor-guided precision drug delivery solutions that combine its AI-native CGM+ wearable biosensor platform with Latch Medical’s Pharma Latch microneedle-based intradermal delivery technology.
The partners plan to use real-time metabolic data from CGM+ to help guide and optimize therapeutic delivery for diabetes, obesity and other metabolic conditions, supporting Trinity Biotech’s goal of an integrated metabolic health platform linking continuous sensing, AI-driven insights and precision delivery. Trinity Biotech’s largest financial investor, Perceptive Advisors, is supporting the planned investment, and management views the convergence of these technologies as a significant long-term opportunity in large metabolic disease markets.